Rasna Therapeutics Current Valuation vs. Cash And Equivalents
| RASP Stock | USD 0 0 900.00% |
For Rasna Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rasna Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rasna Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rasna Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rasna Therapeutics over time as well as its relative position and ranking within its peers.
Rasna |
Rasna Therapeutics Cash And Equivalents vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rasna Therapeutics's current stock value. Our valuation model uses many indicators to compare Rasna Therapeutics value to that of its competitors to determine the firm's financial worth. Rasna Therapeutics is rated below average in current valuation category among its peers. It is rated below average in cash and equivalents category among its peers creating about 0.01 of Cash And Equivalents per Current Valuation. The ratio of Current Valuation to Cash And Equivalents for Rasna Therapeutics is roughly 116.29 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Rasna Therapeutics' earnings, one of the primary drivers of an investment's value.Rasna Cash And Equivalents vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Rasna Therapeutics |
| = | 1.22 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Rasna Therapeutics |
| = | 10.52 K |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Rasna Cash And Equivalents Comparison
Rasna Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Rasna Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rasna Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rasna Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Rasna Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Rasna Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Rasna Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rasna Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rasna Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rasna Therapeutics' important profitability drivers and their relationship over time.
Use Rasna Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rasna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rasna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Rasna Therapeutics Pair Trading
Rasna Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Rasna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rasna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rasna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rasna Therapeutics to buy it.
The correlation of Rasna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rasna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rasna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rasna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Rasna Therapeutics position
In addition to having Rasna Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Candy and Soda Thematic Idea Now
Candy and Soda
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Candy and Soda theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Candy and Soda Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.